14.3.3 ETA, Rheum. Arthritis

Optimal result: 0 – 0.2 Units

14-3-3 eta is a joint-derived pro-inflammatory protein implicated in the erosive process of rheumatoid arthritis (RA); it can be elevated in both early and established disease. The reference range is < 0.20 ng/mL. Clinically, 14-3-3 eta is highly specific for RA and adds ~15% incremental diagnostic sensitivity beyond Rheumatoid Factor (RF) and anti-CCP antibodies, helping identify earlier cases that RF/anti-CCP may miss. Positive levels correlate with greater radiographic joint damage (e.g., Sharp/van der Heijde scoring), and results ≥ 0.50 ng/mL flag a higher risk of faster radiographic progression—even in patients who appear clinically controlled (e.g., SDAI remission). A result within range does not rule out RA and should be interpreted alongside symptoms, examination, imaging, and other labs (RF, anti-CCP, CRP, ESR). An elevated result supports RA in the right clinical context and may justify closer monitoring, imaging baseline, and discussion of treatment optimization.

14-3-3 eta is a protein released from inflamed joint tissue. It acts as a pro-inflammatory mediator and is implicated in the erosive joint damage seen in rheumatoid arthritis (RA). Levels can be elevated in both early and established RA.

Why 14-3-3 eta is tested

RA can be challenging to diagnose early. Traditional markers like Rheumatoid Factor (RF) and Anti-CCP (Cyclic Citrullinated Peptide) antibodies help—but they’re not positive in everyone, especially early on. Serum 14-3-3 eta adds diagnostic sensitivity, helping identify patients who might otherwise be missed.

  • Diagnostic value: 14-3-3 eta is highly specific for RA. In early disease, it can provide about a 15% incremental detection benefit on top of RF and Anti-CCP—meaning ~15% more early RA patients may be identified when this marker is included alongside those tests.

  • Disease activity & prognosis: Positive 14-3-3 eta is associated with higher rates of radiographic joint damage (e.g., Sharp/van der Heijde scoring). Levels ≥ 0.50 ng/mL have been linked to more rapid radiographic progression, even in patients who appear clinically quiet (e.g., in SDAI remission).

How to interpret results for 14-3-3 eta

  • Within reference (< 0.20 ng/mL):
    This is considered negative. A value in range does not rule out RA, especially if symptoms (joint pain, morning stiffness, swelling) persist. Your clinician will weigh this result with symptoms, exam, imaging, and other labs (RF, Anti-CCP, CRP, ESR).

  • Elevated (≥ 0.20 ng/mL):
    Supports an RA diagnosis when considered with clinical findings.

    • ≥ 0.50 ng/mL: Signals higher risk for faster joint damage progression on imaging, even if you’re feeling relatively well. This level may prompt closer monitoring and a discussion about earlier or more targeted therapy.

What affects the result of 14-3-3 eta

14-3-3 eta reflects joint-derived inflammation and erosive activity. Levels may shift with disease activity and treatment response. Your provider may trend this marker over time together with clinical scores (e.g., SDAI, DAS28) and imaging.

What to do next

  • If elevated:

    • Discuss results promptly with your rheumatologist.

    • Ask whether your current treatment plan adequately addresses progression risk, especially if ≥ 0.50 ng/mL.

    • Consider combining this marker with RF, Anti-CCP, CRP, ESR, and (when appropriate) ultrasound or X-ray to establish a baseline and monitor change.

  • If in range but symptoms persist:

    • A negative result doesn’t exclude RA. Keep a symptom diary (duration of morning stiffness, swollen joints, fatigue).

    • Follow up for a full work-up: exam, imaging, and complementary labs.

Related tests

  • RF and Anti-CCP antibodies: Core RA serologies.

  • CRP and ESR: Systemic inflammation/activity.

  • Imaging: Ultrasound, X-ray/MRI for erosions and synovitis.

  • Composite indices: SDAI, DAS28 to track control over time.

Key evidence

  • Early detection benefit: Adding 14-3-3 eta to RF and Anti-CCP improves early RA detection by ~15%.

  • Radiographic risk: Positive 14-3-3 eta correlates with higher radiographic damage; ≥ 0.50 ng/mL predicts faster progression, even in SDAI remission.

Notes: This test was developed and analytically validated by the performing laboratory (e.g., Labcorp) and may not be FDA-cleared; it is used for clinical decision-making under applicable regulations. Results should be interpreted by a qualified clinician.

References

  1. Carrier N, et al. Arthritis Res Ther. 2016;18:37.

  2. Maksymowych WP, et al. Arthritis Res Ther. 2014;16:R99.

14.3.3 ETA, Rheum. Arthritis
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond 14.3.3 ETA, Rheum. Arthritis — 10,000+ markers explained
One 14.3.3 ETA, Rheum. Arthritis result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro